

Next Gen Diagnostics Announces that Cleveland Clinical Microbiology Lab Medical Director Daniel Rhoads has Joined its Scientific Advisory Board

September 19, 2022 - Boston, Massachusetts – FOR IMMEDIATE RELEASE

Next Gen Diagnostics announces that Cleveland Clinic Microbiology Laboratory Medical Director Dr. Daniel Rhoads has joined its Scientific Advisory Board. Dr. Rhoads, a thought leader in clinical microbiology diagnostics practice, is in charge of world-leading medical center Cleveland Clinic's bacteriology operations.

"We recognize reducing the cost and increasing the rapidity of analyzing a pathogen's whole genome sequence will unlock information that can enable us to better care for the sick. NGD has assembled automation for both sample preparation and bioinformatics analysis to enable the translation of microbial genomic sequencing from science to medicine. I am pleased to join NGD's Scientific Advisory Board to help advise them in the clinical validation and practical implementation of pathogen sequencing for use in patient care," said Dr. Rhoads.

NGD has combined world-class fully automated bioinformatics, validated in published clinical studies, with a revolutionary microfluidic sample preparation system to offer a low cost, overnight complete pathogen WGS service. NGD's exclusive microfluidic sample preparation system reduces reagent volumes >10-fold, and is highly compact and automated, enabling 48 bacterial samples to be simultaneously processed in an instrument the size of a desktop computer using a disposable the size of a single plate.

"Dan was a trusted and valued informal advisor to my prior company, Specific Diagnostics, where his laboratory at the Cleveland Clinic participated in Specific's FDA clinical trials. I am gratified that he will now more formally join NGD, as a member of our distinguished Scientific Advisory Board," said Dr. Paul A. Rhodes, CEO. "His visionary perspective aligns with the path NGD has charted in bringing low-cost, user-friendly pathogen WGS services to practical clinical microbiology. I look forward to benefitting again from Dan's insights as we pursue this new mission."

About Next Gen Diagnostics

NGD, founded with Sanger Institute group leaders, has built and validated the world-leading automation of pathogen bioinformatics necessary to enable high throughput low cost clinical use of WGS. In addition, NGD holds the exclusive rights to a revolutionary microfluidic system for all clinical and commercial applications of pathogen WGS. NGD offers high volume turn-key sequencing services to enable detection of transmission in hospitals, and is working with leading collaborators in the US, Europe and Israel to be the first to bring WGS-based regulated diagnostics to patient care. NGD is based in the US, with an office in Cambridge, UK and a subsidiary in Israel. For press inquiries, please contact: press@nextgen-dx.com